| Literature DB >> 33442407 |
Shiyu Liu1,2,3, Qin Zhao1,2,3, Weiyan Shi1,2,3, Zhuangzhuang Zheng1,2,3, Zijing Liu1,2,3, Lingbin Meng4, Lihua Dong1,2,3, Xin Jiang1,2,3.
Abstract
High-grade gliomas (HGGs) are the most common primary malignant brain tumors. They have a high degree of malignancy and show invasive growth. The personal treatment plan for HGG is based on the patient's age, performance status, and degree of tumor invasion. The basic treatment plan for HGG involves tumor resection, radiotherapy (RT) with concomitant temozolomide (TMZ), and adjuvant TMZ chemotherapy. The basic radiation technology includes conventional RT, three-dimensional conformal RT, intensity-modulated RT, and stereotactic RT. As our understanding of tumor pathogenesis has deepened, so-called comprehensive treatment schemes have attracted attention. These combine RT with chemotherapy, molecular targeted therapy, immunotherapy, or tumor-treating fields. These emerging treatments are expected to improve the prospects of patients with HGG. In the present article, we review the recent advances in RT and comprehensive treatment for patients with newly diagnosed and recurrent HGG. © The author(s).Entities:
Keywords: High-grade glioma; Immunotherapy; Molecular targeted drugs; Radiotherapy; Tumor-treating fields
Year: 2021 PMID: 33442407 PMCID: PMC7797642 DOI: 10.7150/jca.51107
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207